HiFiBiO Therapeutics, a biotechnology company with expertise in immune modulation and drug intelligent science, announced the completion of an oversubscribed $75M Series D financing round.

The funding was led by the new investor Mirae Asset Financial Group. B Capital Group, Sherpa, Maison Capital, Trinity Innovation Fund, Grand Mount, and HKSTP Venture Fund also participated in this round. The existing shareholders IDG, Sequoia, Legend Star, and Hengxu continued to invest.